Merck & Co Inc header image

Merck & Co Inc

MRK

Equity

ISIN null / Valor 10683053

New York Stock Exchange, Inc (2026-10-30)
USD 149.52+2.18%

Merck & Co Inc
UMushroom community rating:

star star star star star
4.20 9 votes No rating yet
NegativeNeutralPositive

About company

Merck & Co., Inc. (known as MSD outside the United States and Canada) is a global, research-driven pharmaceutical company that discovers, develops, manufactures and markets prescription medicines, vaccines and animal health products. Headquartered in Rahway, New Jersey, it sells treatments across oncology, infectious disease, cardiometabolic and immunology areas, with high-profile products such as the immuno‑oncology therapy pembrolizumab (Keytruda) and the HPV vaccine Gardasil anchoring its portfolio; it also operates a significant animal health division. The company generates revenue through worldwide commercialization of patented drugs and vaccines, supports those sales with sustained R&D investment and collaborations to advance a pipeline of small molecules, biologics and vaccine candidates, and is publicly traded on the New York Stock Exchange under the ticker MRK.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

73.3%1Y
45.6%3Y
69.8%5Y

Performance

29.1%1Y
26.8%3Y
24.9%5Y

Volatility

Market cap

368892 M

Market cap (USD)

Daily traded volume (Shares)

12,345,380

Daily traded volume (Shares)

1 day high/low

99.38 / 98.28

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.20

9 votes
Performance:
starstarstarstarstar
4.16
Innovation:
starstarstarstarstar
4.20
Society:
starstarstarstarstar
4.28
Nature:
starstarstarstarstar
3.64
Kyan Bailey
UK, 23 Oct 2026
star star star star star
A strong pharmaceutical company supported by Keytruda, with promising cancer vaccine developments and earnings due on 29 October. pcoming oncology updates offer potential upside, although slowing Keytruda growth and patent-expiry concerns limit its appeal.
Viktor Scialdone
Netherlands, 16 Oct 2026
star star star star star
A solid company with strong cash flow, but almost half of its sales come from one cancer drug, Keytruda, which loses patent protection from 2028. New medicines like Winrevair are growing fast and could fill the gap. After a strong rise this year, the stock is no longer cheap.
Lewis Bastos
Spain, 09 Feb 2026
star star star star star
A good investment with solid earnings

EQUITIES OF THE SAME SECTOR

Galapagos NV
Galapagos NV Galapagos NV Valor: 2130343
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.07%EUR 28.92
Terveystalo Oyj
Terveystalo Oyj Terveystalo Oyj Valor: 37893402
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.50%EUR 6.04
Siemens Healthineers AG
Siemens Healthineers AG Siemens Healthineers AG Valor: 40652181
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%EUR 42.89
Beiersdorf AG
Beiersdorf AG Beiersdorf AG Valor: 324660
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.48%EUR 82.80
Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA Fresenius SE & Co. KGaA Valor: 332902
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.69%EUR 47.80
Carl Zeiss Meditec AG
Carl Zeiss Meditec AG Carl Zeiss Meditec AG Valor: 1055489
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.63%EUR 34.98
Fresenius Medical Care AG
Fresenius Medical Care AG Fresenius Medical Care AG Valor: 520878
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.58%EUR 40.40
Denali Therapeutics Inc
Denali Therapeutics Inc Denali Therapeutics Inc Valor: 39149539
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.97%USD 18.94
Dermapharm Holding SE
Dermapharm Holding SE Dermapharm Holding SE Valor: 40166352
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%EUR 38.55
Formycon AG
Formycon AG Formycon AG Valor: 12194189
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.15%EUR 18.88